Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953661 · ClinicalTrials.gov registry record · NA
Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome
A NA study, sponsored by Stanford University.
- Not yet
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT06953661: Clinical Trial NA study, sponsored by Stanford University.
NCT06953661 is a NA study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06953661, a NA study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.
Interventions
- DRUG Normal saline
- DRUG Ropivacaine
- PROCEDURE Stellate ganglion block
- PROCEDURE Sham injection of saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2026-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06953661
The ClinicalTrials.gov registry entry for NCT06953661 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Normal saline is the first listed.
NCT06953661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06953661 about?
NCT06953661 is a clinical study titled "Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome". This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention fo...
What is the current status of trial NCT06953661?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-10-13. Estimated completion is 2026-11.
What interventions are being tested in trial NCT06953661?
The interventions under investigation include: Normal saline (DRUG), Ropivacaine (DRUG), Stellate ganglion block (PROCEDURE), Sham injection of saline (PROCEDURE).
Who is sponsoring clinical trial NCT06953661?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.